

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 500862001810

Application Number 10/756,774

Applicant


Alan M. EZRIN, Ph.D. et al.

Filing Date January 12, 2004

Group Art Unit Not Yet Assigned

Mailing Date

February 23, 2004



## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
J	1.	11/30/82	*4,361,553	Loh et al.	—	—	
J	2.	07/1984	*4,462,941	Lee et al.	7	1	
J	3.	3/26/85	*4,507,234	Kato et al.			
J	4.	1/1/91	*4,981,979	Sivam			
J	5.	5/21/91	*5,017,689	Hruby et al.			
J	6.	2/11/92	*5,087,616	Myers et al.			
J	7.	8/4/92	*5,135,736	Anderson et al.			
J	8.	8/18/92	*5,140,013	Gaudreault et al.			
J	9.	12/8/92	*5,169,933	Anderson et al.			
J	10.	4/26/94	*5,306,809	Boon et al.			
J	11.	12/27/94	*5,376,662	Ockert et al.			
J	12.	6/9/96	*5,482,930	Wei et al.			
J	13.	02/1996	*5,493,007	Burnier et al.			
J	14.	8/20/96	*5,547,667	Angelucci et al.			
J	15.	12/1996	*5,580,853	Sytkowski			
J	16.	03/18/97	*5,612,034	Pouletty, et al.			
J	17.	3/25/1997	*5,614,487	Battersby et al.			
J	18.	08/1997	*5,654,276	Barret et al.			
J	19.	9/15/98	*5,807,827	Lee et al.			
J	20.	8/31/99	*5,945,033	Yen			
J	21.	1/2000	*6,013,263	Barney et al.			
J	22.	1/2000	*6,017,536	Barney et al.			
J	23.	8/2000	*6,103,236	Suzawa et al.			
J	24.	8/2002	*6,437,092	Ezrin et al.			
J	25.		*09/623,533	Bridon, et al.	1	1	9/5/2000
J	26.		*09/623,548	Bridon, et al.	—	—	9/5/2000

EXAMINER:

DATE CONSIDERED:

12/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 500862001810	Application Number 10/756,774
	Applicant  Alan M. EZRIN, Ph.D. et al.	
	Filing Date January 12, 2004	Group Art Unit Not Yet Assigned
	Mailing Date  February 23, 2004	

27.		*09/657,276	Bridon, et al.	—	—	9/7/2000
28.		*09/657,295	Bridon, et al.	—	—	9/7/2000

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
J	29.	12/1993	*9325217	PCT	—	—		
J	30.	04/1995	*9510302	PCT				
	31.	03/1996	*9606626	PCT				
	32.	6/13/91	*9108220	PCT				
	33.	1/8/98	*9800171	PCT				
	34.	5/20/99	*9924074	PCT				
	35.	05/1999	*9924075	PCT				
	36.	05/1999	*9924462	PCT				
	37.	09/1999	*9948536	PCT				
	38.	04/1994	*0602290	EPO				
	39.	3/19/98	*2,265,861	Canada				
	40.	1/19/95	*9501806	PCT				
	41.	12/21/00	*0076550 A2	PCT				
	42.	12/21/00	*0076551 A2	PCT				
	43.	8/11/93	*0554708 A1	EPO				
	44.	7/1997	*9723243	PCT				
J	45.	1/1993	*4122210	Germany	—	—		

EXAMINER:

DATE CONSIDERED:


12/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 500862001810	Application Number 10/756,774
	Applicant  Alan M. EZRIN, Ph.D. et al.	
	Filing Date January 12, 2004	Group Art Unit Not Yet Assigned
	Mailing Date  February 23, 2004	

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	46.	*Cancer Research, 1986, 46, 467-473.
	47.	*Bioorg. & Med. Chem. Lett., 1997, 7, (5), 617-622.
	48.	*J. Med. Chem., 1998, 41, 2701-2708.
	49.	*Chem. Pharm. Bull., 1997, 45, (2), 399-401.
	50.	*J. Pharm. Sci., 1998, 87 (3), 338-346.
	51.	*Anti-cancer Drugs, 1999, 10, 785-790.
	52.	*Clinical Cancer Research, 1999, 5, 753-759.
	53.	*European J. Cancer, 1995, 31A (2), 283-284.
	54.	*J. Pharm. & Experimental Therapeutics, 1981, 219 (2), 389-393.
	55.	*Ann. NY Acad. Sciences, 1971, 186, 284-286.
	56.	*International J. Pharmaceutics, 1991, 67, 177-184.
	57.	*International J. Pharmaceutics, 1993, 89, 91-102.
	58.	*Proc. Natl. Acad. Sci., 1996, 93 (5), 2186-2191.
	59.	*Anti-Cancer Drugs, 1997, 8, 677- 685.
	60.	*Anti-Cancer Research, 1994, 14, 1943-1950.
	61.	*Neoplasma, 1988, 35, (3), 329-342.
	62.	*Neoplasma, 1988, 35, (3), 343-349.
	63.	*Anti-Cancer Drugs, 1997, 8, 835-844.
	64.	*J. Surgical Research, 1991, 50, 156-162.
	65.	*Anti-Cancer Drugs, 1999, 10, 405-411.
	66.	*European J. Nucl. Med., 1995, 22 (9), 989-996.
	67.	*Biol. Pharm. Bull., 1998, 21, (1), 56-61.
	68.	*Br. J. Cancer, 1993, 67, 274-278.

EXAMINER:

DATE CONSIDERED:

12 / 05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 500862001810	Application Number 10/756,774
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Applicant Alan M. EZRIN, Ph.D. et al.	
		Filing Date January 12, 2004	Group Art Unit Not Yet Assigned
		Mailing Date February 23, 2004	
<p style="text-align: center;"><b>OTHER DOCUMENTS</b> <i>(including author, title, Date, Pertinent Pages, Etc.)</i></p>			
	69.	*Nucl. Med. Biol., 1992, 19 (6), 685-695.	
	70.	*Drug Delivery, 1999, 6, 89-95.	
	71.	*Cancer Research, 1993, 53, 4238-4242.	
	72.	*Science, 1993, 261, 212-215.	
	73.	*Biotech Report, 1994/1995, 106-107.	
	74.	*Proceedings of the 8th American Peptide Symposium, 1983, 409-412.	
	75.	*Int. J. Biochem. Cell. Biol. 1998, 30, 1281-1284.	
	76.	*Endocrinology, 1982, 110 (3), 1049-1051.	
	77.	*J. Biol. Chem. 1995, 270 (43), 25344-25347.	
	78.	*J. Dev. Physiol., 1989, 12, 55-62.	
	79.	*Biopolymers (Peptide Science), 1998, 47, 451-463.	
	80.	*Ann. Rev. Neurosci, 1984, 7, 223-255.	
	81.	*Chem. Pharm. Bull. 1979, 27, (8), 1942-1944.	
	82.	*Proc. Natl. Acad. Sci. 1986, 83, 265-269.	
	83.	*TINS, 1993, 16, 403-409.	
	84.	*Methodological Surveys in Biochemistry and Analysis, 15, 1985.	
	85.	*Metodol. Surv. Biochem Anal., vol. 15, 1985, pp. 109-114.	
	86.	*Indian Journal of Biochemistry & Biophysics, 30, 4/93.	
	87.	*Indian J. Biochem. Biophys., vol. 30, no. 2, 1993, pp. 117-122.	
	88.	*J. of Histochemistry and Cytochemistry, 32, (9), 1984.	
	89.	*J. Histochem. Cytochem, vol. 32, no. 9, 1984, pp. 945-957.	
	90.	*Cell Tissue Res. 215 (3), 1981.	
	91.	*Cell Tissue Res., vol. 215, no. 3, 1981, pp. 577-589.	
	92.	*Int. Congr. Ser. Excerpta Medica, vol. 471, 1978, pp. 177-186.	
93.	*Febs Letters, vol. 70, no. 1, 1976.		
94.	*Analytical Biochemistry, vol. 215, no. 1, 1993, pp. 1-8		
EXAMINER:		DATE CONSIDERED: 12/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 500862001810	Application Number 10/756,774
	Applicant  Alan M. EZRIN, Ph.D. et al.	
	Filing Date January 12, 2004	Group Art Unit Not Yet Assigned
	Mailing Date  February 23, 2004	

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

- |      |   |
|------|---|
| 95.  | *Filho, Pharm Sci. 2, 1996, pp. 199-201.                                |
| 96.  | *Correa, Pharm Sci. 3, 1997, pp. 67-71.                                 |
| 97.  | *Peptide Research 8 (3) 1995, pp. 124-137.                              |
| 98.  | *The J. of Pharm & Experimental Therapeutics, 280, 1997, pp. 1210-1214. |
| 99.  | *Blood Cells, Molecules and Diseases 23 (3), 1997, pp. 58-68.           |
| 100. | *Abstract JP 59138958, 1984, Mitsubishi Chemical Industries Co. JP.     |
| 101. | *Database Biosis, Accession No. XP-002172298                            |
| 102. | *Patent Abstracts of Japan No. 62138430                                 |
| 103. | *Biochimica et Biophysica Acta, 1991, 1118, 83-90                       |
| 104. | *J. Med. Chem., 2000, 43, 1253-1256                                     |
| 105. | *J. Med. Chem., 1998, 41, 853-863                                       |
| 106. | *Allergie et Immunologie, 1996, 28, 186-191                             |
| 107. | *European J. Pharmaceutical Sciences, 1996, 4, 307-319                  |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.